ANAVEX®1037

Anavex® has discovered and developed several drugs targeting different types of cancer. These cancer compounds are at various stages of pre-clinical development and may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels that enables cancer to grow), and tumor cell proliferation.

In advanced pre-clinical studies, our cancer drugs revealed significant anti-tumor potential in validated animal models – significantly suppressing tumor growth in immune-deficient mice models – without toxic side effects. Importantly, our compounds selectively kill human cancer cells without affecting normal/healthy cells.

ANAVEX®1037

ANAVEX®1037 is designed for the treatment of prostate cancer. It is a low molecular weight, synthetic compound exhibiting high affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar levels. In advanced preclinical studies, this compound revealed antitumor potential with no toxic side effects. It has also been shown to selectively kill human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient mice models. Scientific publications describe sigma receptor ligands positively, highlighting the possibility that these ligands may stop tumor growth and induce selective cell death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.